ITI Scotland has new MD, extended research and third annual members meeting
David Creed, Group CEO of ITI Scotland, said the recent third annual members meeting of over 200 members "revealed new programme opportunities and further prospects for R&D and commercial activity" in the energy, life science and techmedia sectors for the coming year. "
Many members exhibited their own technologies to the audience. As well
as offering the chance to communicate,
"the meeting clearly demonstrated Duncan Botting
that, with nine commercial deals after only 3½ years of programme development, ITI Scotland is delivering on its targets. Everyone involved is very excited by what lies ahead,” he said. This month ITI Scotland appointed ABB's former head of Technology and business development, and smart grid development expert, Duncan Botting as its new MD.
On the life science front, ITI Life Sciences, it is extending its research programme designed to develop new technologies for use in the pharmaceutical industry to predict the effects of drug compounds in the human body. The research programme, which has exceeded expectations in delivering new technologies and intellectual assets (know-how and patents), will be extended from 4 February 2008 for up to 14 months and receive a further £2million in funding
The three-year Transgenic Screening and Safety Models (TSM) programme was initiated by in February 2005 with CXR Biosciences (Dundee, Scotland) and TaconicArtemis GmbH (Cologne, Germany).
The programme extension has been granted to complete the commercial packages on the additional technologies developed beyond those originally targeted. The technologies developed are transgenic mouse lines, in which key murine proteins responsible for drug metabolism in the cytochrome P450, nuclear receptor (CAR and PXR) and transporter families, have now been replaced by their human counterparts.
The newer models allow the generation of this data in pre-clinical models that behave in a similar way to man, thereby reducing species differences between mice and humans and providing more predictive data to drug discovery teams.
Set up by Scottish Enterprise, ITI has three divisions – ITI Energy, ITI Life Sciences and ITI Techmedia – and the publicly funded company has an active Membership programme of interested parties from the business, research, academic and public sectors.
Source:http://www.itiscotland.com/